Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
Smith
Michael
M
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000473:pathology; D002170:Canada / Q000453:epidemiology; D018572:Disease-Free Survival; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D011639:Public Opinion; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab